STOCK TITAN

Bausch Health Companies (BHC) Stock News, May-Aug 2022

BHC NYSE

Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.

Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.

Rhea-AI Summary

Bausch Health Companies Inc. reported second-quarter 2022 revenues of $1.967 billion, down 6% from $2.1 billion in Q2 2021. The decline was attributed to foreign exchange impacts and divestitures. The company's net loss decreased to $145 million compared to $595 million the previous year. Operating income improved significantly to $161 million. Bausch Health is appealing a court decision concerning XIFAXAN patent litigation and is committed to strategic alternatives, including a potential spinoff of Bausch + Lomb, despite ongoing challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.30%
Tags
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to appeal a recent U.S. District Court ruling regarding its XIFAXAN® patents. The court ruled the patents for the treatment of overt hepatic encephalopathy as valid but declared those for irritable bowel syndrome with diarrhea invalid. Bausch intends to challenge this ruling vigorously and prevent Norwich Pharmaceuticals from launching a generic version of XIFAXAN® until at least 2029. The FDA is also revising guidance for rifaximin, which may impact future generic approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.24%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its second-quarter financial results on August 9, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow, providing insights into the company's performance and business updates. Interested parties can access the materials through the Investor Relations section of Bausch Health's website. The company is focused on improving lives through its diverse portfolio in various health sectors, including gastroenterology and dermatology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.24%
Tags
News
Rhea-AI Summary

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has appointed Thomas W. Ross, Sr. as the new chair of the Board of Directors following the resignation of Joseph C. Papa. Mr. Papa remains CEO until a successor is found. The Board is actively searching for a new CEO while affirming the company's full-year guidance for 2022, initially announced on June 8. The company aims to complete its spinoff from Bausch Health (NYSE/TSX: BHC) in 2023, contingent on various approvals and market conditions, with no reported disagreements leading to Mr. Papa's departure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) and Salix Pharmaceuticals announced the winners of the 2022 Salix Gastrointestinal Health Scholars Program, awarding $10,000 each to 10 students living with gastrointestinal diseases. This marks the third consecutive year of the program which received over 150 applications. The scholarship aims to assist students in their academic pursuits amid health challenges. The recipients span undergraduate and graduate categories, showcasing the company's commitment to supporting education for those impacted by GI conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the results of its 2022 annual meeting of shareholders held on June 21, 2022. All 12 nominated directors were elected, with Thomas J. Appio as CEO expressing gratitude towards former Board member Joseph C. Papa who resigned. John A. Paulson fills the vacancy and will serve as Board Chair. Shareholders approved executive compensation, amendments to the 2014 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent auditor until the 2023 meeting. Full voting results will be reported on Form 8-K.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.36%
Tags
management
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) has announced its presentation during the Annual Meeting of Shareholders held on June 21, 2022. The presentation highlights the company's diversified pharmaceutical operations, focusing on improving health outcomes through various products in gastroenterology, neurology, and eye health, primarily via its ownership of Bausch + Lomb. The company has also filed a Form 8-K detailing this presentation, available on its Investor Relations page, reinforcing its commitment to advancing global health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals, will present new data on XIFAXAN® (rifaximin) at the European Association for the Study of the Liver's International Liver Congress™ 2022 in London from June 22-26, 2022. The research focuses on identifying factors precipitating overt hepatic encephalopathy (OHE) and aims to improve management strategies, reducing hospitalization risks. Salix, dedicated to addressing liver disease, emphasizes its role in enhancing patient care through research and development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary

Bausch Health Companies (NYSE/TSX: BHC) announced it is suspending the IPO plans for its Solta Medical business due to challenging market conditions. Solta, a leader in medical aesthetics, offers advanced skin rejuvenation and body contouring solutions. The company aims to focus on driving Solta's revenue and operational milestones while retaining it within the Bausch Health portfolio to aid in deleveraging its balance sheet. CEO Thomas J. Appio expressed confidence in Solta's growth and market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.10%
Tags
none
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that it will present seven research posters for its products XIFAXAN®, TRULANCE®, and PLENVU® at Digestive Disease Week 2022 from May 21-24, 2022, in San Diego, California. The posters highlight significant findings, such as the efficacy of XIFAXAN in managing hepatic encephalopathy and IBS-D, TRULANCE's rapid response in treating IBS-C, and PLENVU’s high-quality bowel cleansing for colonoscopy preparations. The research results will be publicly accessible on DDW's ePoster website starting May 21, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.79%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

Bausch Health Companies (BHC) last closed at $8.22.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately $3.1B.